Clinical Trial Update: A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating chenodeoxycholic acid for cerebrotendinous xanthomatosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebrotendinous Xanthomatosis

Drugs mentioned

• Chenodeoxycholic acid (chenodeoxycholic acid)

Snippet

Sponsor: Leadiant Biosciences, Inc. | Conditions: Cerebrotendinous Xanthomatoses | Phase 3 | Status: WITHDRAWN